Effexor XR (venlafaxin HCI)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.


Approval Status:

Approved October 1997

Specific Treatments:


Find Related Trials for The Following Conditions

General Information

Wyeth-Ayerst Laboratories received marketing clearance from the U.S. Food and Drug Administration for Effexor (R) XR (venlafaxine HCI) Extended-Release Capsules. This is a once-a-day treatment that relieves the symptoms of depression. Clinical trial results also showed that patients receiving Effexor XR for the treatment of depression experienced a reduction in anxiety symptoms.

Side Effects

The most common side effects of Effexor included abnormal dreams, abnormal ejaculation, anorexia, dizziness, dry mouth, nausea, nervousness, somnolence, sweating and tremor.